Optibrium’s Post

🧬 Gilead Teams Up with Genesis Therapeutics: The Future of Small Molecule Drugs? The biotech world is buzzing as Gilead Sciences announces a partnership with AI startup Genesis Therapeutics. Their goal? To accelerate the discovery of small molecule drugs through the power of AI. This collaboration highlights how artificial intelligence is transforming the drug development process, making it faster and more efficient. At MedMind, we’re excited to see how these innovations will drive new treatments and revolutionize patient care. As AI continues to evolve, what impact do you think it will have on drug discovery and the broader pharmaceutical industry? Share your thoughts! https://lnkd.in/g6FCW2zU #AI #DrugDiscovery #Biotech #MedMind #PharmaceuticalInnovation

Congratulations to 2024 Termeer Fellow, Nabanita Nawar, PhD, cofounder and CEO of HDAX Therapeutics, on her company’s remarkable achievement. HDAX Therapeutics has successfully secured an oversubscribed seed financing of $3.2 million, led by industry giants including SeedFolio, FACIT, and TIAP - Toronto Innovation Acceleration Partners. This significant milestone will accelerate HDAX’s journey towards developing pioneering therapeutics targeting HDAC6, showcasing their commitment to addressing unmet medical needs through innovation. With this support, Nabanita and her team are poised to advance their pipeline towards preclinical development, further solidifying their role as leaders in the biotech space. Nabanita's vision and leadership exemplify the values we celebrate at The Termeer Foundation. By fostering an environment where innovation thrives, we continue to support and mentor leaders like Nabanita, driving forward groundbreaking treatments that promise a healthier future for all. Nabanita and her HDAX Therapeutics team’s journey inspires us and underscores the importance of our mission: to empower healthcare innovators until every patient has a cure. #leadership #STEM #TermeerFoundation #HealthcareInnovation #RareDisease #Biotech #Bio #Biotechnology #PatientCare #LifeScience #PeopleEmpoweringCures #ConnectionsEmpoweringCures #LeadershipMatters #Healthcare #Mentorship #Mentor #Science #Leader #CEO #Founder #TermeerFellows

As R&D teams in #Pharma and #BioTech drive innovation with new modalities and personalized medicines, #TechOps face the challenge of removing roadblocks to #Commercialization – production costs and turnaround times. Geoffrey Zassenhaus shares how we helped the CMC team of a leading biotech collaborate to redesign its production processes to reduce costs by a factor of 25 and time to patient by 50%. https://lnkd.in/eDXbbbhf

Why Roche Changed Its Mind 💡 Initially declining to acquire Poseida Biotech in 2023, Roche has now closed a $1.5 billion deal to buy the cell therapy company. But why the turnaround? In August 2022, Roche teamed up with Poseida, paying $110 million upfront. When another Big Pharma offered to acquire Poseida in April 2023, then-CEO Mark Gergen approached Roche, which hinted at future collaborations despite initial disinterest. By mid-2024, Poseida's milestones and new clinical trials rekindled Roche's interest. Intense negotiations followed, leading to an offer Poseida couldn't refuse. This acquisition marks a big step for Roche, focusing on off-the-shelf cell therapies and aiming to expand in the fast-paced biotech landscape 🔬. #Biotech #Pharma #CellTherapy

SmartLabs is proud to support Acera Therapeutics in their mission to develop T cell-directed immunotherapies for cancer. Through our managed service model developed in partnership with a local landlord, we provide hands-on operational and site management, helping to accelerate and strengthen their research. This approach allows emerging biotechs and startups to focus on what matters most: advancing their science. #Infrastructure #Operations #Expertise #Innovation #Technology #LifeSciences #ResearchandDevelopment #Biotech #EarlyDevelopmentResearch #Boston #Massachusetts #Cambridge #Pharma #Pharmaceuticals #Biotech #ClinicalTrials #LifeScience #DrugDevelopment #CellTherapy

Coulter Partners successfully completed a search assignment for Curve Therapeutics and is pleased to announce the placement of Rab Prinjha, PhD, as Chief Research and Development (R&D) Officer. Curve Therapeutics is a private biotechnology company pioneering a revolutionary mammalian cell-based, functional drug discovery platform to address intracellular disease targets. Its mission is to improve patient outcomes by discovering innovative drugs that address the most complex disease targets. Commenting on the collaboration with Coulter Partners, Simon Kerry, Chief Executive Officer of Curve Therapeutics, said: “We were truly impressed with Coulter Partners’ diligence and professionalism throughout the entire recruitment process. Their deep understanding of the market and the specific needs of our R&D team enabled them to identify a pool of highly qualified candidates. Their expert advice and guidance were invaluable in making informed decisions, ultimately leading to the successful placement of Rab as our new Chief R&D Officer.” Read the full press release here: https://lnkd.in/eMdiAvpu #lifesciences #leadership #executivesearch #toptalent Key players for this placement: Kay Wardle PhD, Liam Fryer, Pat Mileham, Ruby Charteris

After productive time off including a trip to the Biotechnology Innovation Organization Conference in San Diego we're back with the next episode of #BioBlast!👏 👏 👏 Devin Zitelman connects with Carsten Brunn, President & CEO, Cartesian Therapeutics (NASDAQ: RNAC), a publicly traded, clinical-stage #biotech company pioneering #mRNA cell therapy for autoimmune diseases. The two discuss the company's $110M reverse-merger with Selecta Biosciences, plus: 🔎 Professional story and career "arcs" that inform his leadership style and management approach. ☕ The integration of founder (Murat Kalayoglu + Michael Singer) and executive teams, approach to culture-building and talent acquisition. 💉 Managing a pipeline of novel assets across multiple indications and phases of clinical trials. 🔭 Differences and advantages of hosting operations in #Boston and #Maryland including their biomanufacturing + GMP facilities. 💰 Trends in venture and development capital. ...and more! 📹 Tune in and subscribe to #BioBlast, now streaming on YouTube & Spotify for Podcasters plus anywhere you access your #podcasts. MassBio Maryland Tech Council Maryland Department of Commerce BioBuzz Nasdaq Frederick Innovative Technology Center, Inc Argot Partners Scheer Partners Velogic The National Institutes of Health Disclaimer: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners employs individuals that own shares in Cartesian Therapeutics stock.

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Former RayzeBio CEO quickly returns with new biotech; Amgen’s global research leader steps down: Ken Song Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and then a $4.1 billion exit to Bristol Myers Squibb just months after that Nasdaq debut. Now, he’s founder, chair and CEO of a new biotech called Candid Therapeutics, according to his LinkedIn. The roles started in May, according to his profile on the job networking site. The company is working on biologics in the autoimmune field, according to a job posting. With about two decades of leadership experience at biotech startups, a diagnostics company and a healthcare VC firm, Song is ready for his next post. “I’ve actually been looking at quite a few things already. I love that part of just building and pursuing innovation,” Song told Endpoints News in early March. “I’m usually not one to sit idle, so I have been looking at a fair number of different potential interesting opportunities on the company side. I’m unlikely to go back to being an investor.” It’s unclear who is funding Candid at this time. The RayzeBio deal led to a big payday for Song. The cash value of shares he and his family trust beneficially owned came out to $101 million, according to an SEC filing on Bristol Myers’ tender offer. He also had about $70 million in cash value from “in-the-money options,” according to the paperwork. — Kyle LaHucik Ray Deshaies → Amgen SVP of global research Ray Deshaies wrote on LinkedIn that Angela Coxon will take over his role on an interim basis. Coxon has been with Amgen since 1999 and spent the last three years as VP of discovery oncology research. In his LinkedIn post, Deshaies touched on some of the molecules that defined his tenure: the KRAS G12C drug sotorasib (now marketed as Lumakras), the obesity candidate MariTide and the siRNA heart drug olpasiran, among others. “Stepping down from my leadership role has led me to reflect on my time at Amgen over the past 7 years. This reflection has triggered two emotions: gratitude and pride,” he said. “It has been a tremendous privilege to have such an awesome set of colleagues as I have been blessed with at Amgen. It has been an experience — and opportunity — of a lifetime.” Eric Cox → As momentum builds with its Boehringer Ingelheim-partnered weight loss drugs, Zealand Pharma has selected Eric Cox as chief commercial officer. He begins on Aug. 5 and comes from Carmot Therapeutics, where he was VP, commercial strategy and business development. Roche’s $2.7 billion deal for Carmot is off to an auspicious start with early readouts for two obesity drugs, CT-388 and CT-996. Cox had a 16-year career with Merck before his appointment at AstraZeneca… #lucidquest #genetherapy #celltherapy

Liang Schweizer, PhD, Founder & CEO of HiFiBiO Therapeutics, shares how the company stands out in biotech and uses AI to transform drug development on #NYSEFloorTalk with Judy Khan Shaw.

HiFiBiO Therapeutics Founder, Chairperson, and CEO Liang Schweizer sits down with NYSE Floor Talk to discuss how HiFiBiO Therapeutics is revolutionizing the development of immunotherapies through AI/ML to enhance the probability of success in patients suffering from cancer and I&I diseases.      #HiFiBiOWay #Interview #Immunotherapies #Innovation #NYSEFloorTalk